Print

New ANDA Cases

Case Name Date Filed Judge Drug Patent No(s).
Novartis Pharma. Corp. v. Alvogen Pine Brook, Inc., 13-0052 (D. Del.) Jan. 4, 2013 Hon. Richard G. Andrews Exelon® Patch (rivastigmine transdermal system or extended-release film) 6,316,023; 6,335,031
AstraZeneca AB v. Dr. Reddy’s Labs., Inc., 13-0091 (D.N.J.) Jan. 4, 2013 Hon. Joel A. Pisano Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) 6,926,907; 5,714,504; 7,745,466; 7,411,070; 6,369,085
Allergan, Inc. v. Apotex Inc., 13-0016 (M.D.N.C.) Jan. 8, 2013 Hon. Catherine C. Eagles Latisse® (bimatoprost topical solution, 0.03%) 8,263,054
Cadence Pharma., Inc. v. Fresenius Kabi USA, LLC, 13-0139 (S.D. Ca.) Jan. 17, 2013 Hon. Dana M. Sabraw Ofirmev® (acetaminophen for injection) 6,028,222; 6,992,218
Horizon Pharma, Inc. v. Par Pharma. Cos., Inc., 13-0102 (D. Del.) Jan. 17, 2013 Hon. Leonard P. Stark Duexis® (famotidine / ibuprofen tablets) 8,309,127; 8,318,202
Cadence Pharma., Inc. v. Fresenius Kabi USA, LLC, 13-0453 (N.D. Ill.) Jan. 18, 2013 Hon. Gary Feinerman Ofirmev® (acetaminophen for injection) 6,028,222; 6,992,218
Jazz Pharma., Inc. v. Amneal Pharma., LLC, 13-0391 (N.J.D) Jan. 18, 2013 Hon. Esther Salas Xyrem® (sodium oxybate oral solution) 6,472,431; 6,780,889; 7,262,219; 7,851,506; 7,895,059; 8,263,650; 8,324,275
Endo Pharma. Inc. v. Impax Labs., Inc., 13-0435 (S.D.N.Y.) Jan. 18, 2013 Hon. Thomas P. Griesa Opana® ER (oxymorphone hydrochloride extended-release tablets) 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,309,060; 8,329,216
Endo Pharma. Inc. v. Actavis, Inc., 13-0436 (S.D.N.Y.) Jan. 18, 2013 Hon. Thomas P. Griesa Opana® ER (oxymorphone hydrochloride extended-release tablets) 7,851,482; 8,114,383; 8,192,722; 8,309,122; 8,309,060; 8,329,216
Hoffman-La Roche Inc. v. Aurobindo Pharma Ltd., 13-0124 (D. Del.) Jan. 22, 2013 Hon Leonard P. Stark Boniva® Once-Monthly (ibandronate sodium tablets) 7,718,634; 7,410,957; 6,294,196
Glenmark Generics Ltd. v. GlaxoSmithKline, PLC, 13-0135 (D. Del.) Jan. 24, 2013 Hon. Christopher J. Burke Bactroban® (mupirocin calcium cream) 6,025,389; 5,569,672
AbbVie, Inc. v. Sun Pharma. Indus. Ltd., 13-0138 (D. Del.) Jan. 24, 2013 Hon. Gregory M. Sleet Zemplar® (paricalcitol capsules) 5,597,815
Pfizer Inc. v. Wockhardt Ltd., 13-0143 (D. Del.) Jan. 25, 2013 Hon. Gregory M. Sleet Lyrica® (pregabalin oral solution) 6,197,819
Santarus, Inc. v. Mylan Inc., 13-0145 (D. Del.) Jan. 28, 2013 Hon. Richard G. Andrews Fenoglide® (fenofibrate orally disintegrating tablets) 7,658,944; 8,124,125
Auxilium Pharma., Inc. v. Upsher-Smith Labs., Inc., 13-0148 (D. Del.) Jan. 28, 2013 Hon. Sue L. Robinson Testim® (testosterone transdermal gel) 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; 8,063,029; 8,178,518
Depomed, Inc. v. Purdue Pharma L.P., 13-0571 (D.N.J.) Jan. 29, 2013 Hon. Joel A. Pisano OcyContin® (oxycodone hydrochloride controlled-release tablets) 6,340,475; 6,635,280; 6,723,340
Santarus, Inc. v. Mylan Pharma., Inc., 13-0017 (N.D.W.V.) Jan. 30, 2013 Hon. Irene M. Keeley Fenoglide® (fenofibrate orally disintegrating tablets) 7,658,944; 8,124,125
Purdue Pharma L.P. v. Epic Pharma, LLC, 13-0683 (S.D.N.Y.) Jan. 30, 2013 Hon. Sidney H. Stein OcyContin® (oxycodone hydrochloride extended-release tablets) 7,674,799; 7,674,800; 7,683,072
Purdue Pharma L.P. v. Impax Labs., Inc., 13-0684 (S.D.N.Y.) Jan. 30, 2013 Hon. Sidney H. Stein OcyContin® (oxycodone hydrochloride extended-release tablets) 7,674,799; 7,674,800; 7,683,072
Merck Sharp & Dohme Corp. v. APP Pharma., Inc., 13-0166 (D. Del.) Jan. 31, 2013 Hon. Richard G. Andrews Integrilin® (eptifibatide injection) 5,807,825; 5,747,447; 5,968,902
Purdue Pharma L.P. v. Watson Labs., Inc.—Florida, 13-0762 (S.D.N.Y.) Feb. 1, 2013 Hon. Sidney H. Stein OcyContin® (oxycodone hydrochloride extended-release tablets) 8,309,060
Purdue Pharma L.P. v. Impax Labs., Inc., 13-0763 (S.D.N.Y.) Feb. 1, 2013 Hon. Sidney H. Stein OcyContin® (oxycodone hydrochloride extended-release tablets) 8,114,383; 8,309,060
Cadence Pharma., Inc. v. Sandoz Inc., 13-0278 (S.D. Ca.) Feb. 4, 2013 Hon. John A. Houston Ofirmev® (acetaminophen for injection) 6,028,222; 6,992,218
Cadence Pharma., Inc. v. Sandoz Inc., 13-0733 (D.N.J.) Feb. 5, 2013 Hon. Freda L. Wolfson Ofirmev® (acetaminophen for injection) 6,028,222; 6,992,218
Sucampo AG v. Anchen Pharma., Inc., 13-0202 (D. Del.) Feb. 7, 2013 Hon. Gregory M. Sleet Amitiza® (lubiprostone capsules) 6,414,016; 7,795,312; 8,026,393; 8,071,613; 8,097,653; 8,338,639
Unimed Pharma., LLC v. Perrigo Co., 13-0236 (D. Del.) Feb. 15, 2013 Hon. Leonard P. Stark AndroGel® (testosterone gel) 6,503,894
Novartis Pharma. Corp. v. Actavis LLC, 13-1028 (D.N.J.) Feb. 20, 2013 Hon. Susan D. Wigenton Zometa® (zoledronic acid for injection); Reclast® (zoledronic acid for injection) 7,932,241; 8,052,987; 8,324,189
Purdue Pharma L.P. v. Watson Labs., Inc.—Florida, 13-1272 (S.D.N.Y.) Feb. 25, 2013 Hon. Sidney H. Stein OcyContin® (oxycodone hydrochloride extended-release tablets) 8,337,888
Depomed, Inc. v. Watson Labs., Inc.—Florida, 13-0342 (D. Del.) Feb. 28, 2013 Hon. Sue L. Robinson Glumetza® (metformin hydrochloride extended-release tablets) 6,488,962; 6,723,340; 6,635,280; 6,340,475
Eli Lilly and Co. v. Accord Healthcare, Inc., USA, 13-0335 (S.D. Ind.) Feb. 28, 2013 Hon. William T. Lawrence Alimta® (pemetrexed disodium for injection) 7,772,209
Endo Pharma. Inc. v. Watson Pharma., Inc., 13-0192 (E.D. Tex.) Feb. 28, 2013 Hon. J. Rodney Gilstrap Fortesta® (testosterone gel) 6,319,913; 6,579,865
AbbVie Inc. v. The Kennedy Trust for Rheumatology Research, 13-1358 (S.D.N.Y.)  Feb. 28, 2013 Hon. Paul A. Crotty Humira® (adalimumab) 8,298,537; 8,383,120
G.D. Searle LLC v. Lupin Pharma., Inc., 13-0121 (E.D. Va.) Mar. 5, 2013 Hon. Arenda L. Wright Allen Celebrex® (celecoxib capsules) RE44,048
Novartis Pharma. Corp. v. Alvogen Pine Brook, Inc., 13-0370 (D. Del.) Mar. 7, 2013 Hon. Richard G. Andrews Exelon® Patch (rivastigmine transdermal system or extended-release film) 6,316,023; 6,335,031
Novartis Pharma. Corp. v. Actavis, Inc., 13-0371 (D. Del.) Mar. 7, 2013 Hon. Richard G. Andrews Exelon® Patch (rivastigmine transdermal system or extended-release film) 6,316,023; 6,335,031
Merck, Sharp & Dohme Corp. v. Hetero USA Inc., 13-1402 (D.N.J.) Mar. 7, 2013 Hon. Jerome B. Simandle Sustiva® (efavirenz tablets) 6,639,071; 6,939,964; 6,673,372
Janssen Products, L.P. v. Hetero Drugs, Ltd., 13-1444 (D.N.J.) Mar. 8, 2013 Hon. William H. Walls Prezista® (darunavir) 7,126,015; 7,595,408
Intendis Gmbh v. Glenmark Generics Ltd., 13-0421 (D. Del.) Mar. 14, 2013 Hon. Sue L. Robinson Finacea® (azelaic acid gel) 6,534,070
Apotex, Inc. v. Teva Pharma. Indus., Ltd., 13-60601 (S.D. Fl.) Mar. 14, 2013 Hon. Donald M. Middlebrooks Accupril® (quinapril hydrochloride) 6,531,486
Boehringer Ingelheim Pharma Gmbh & Co. KG v. Kremers Urban Pharma. Inc., 13-1580 (D.N.J.) Mar. 14, 2013 Hon. Noel L. Hillman Aggrenox® (dipyridamole / aspirin extended-release capsules) 6,015,577
Pharmacia & Upjohn Co. LLC v. Apotex Inc., 13-2034 (N.D. Ill.) Mar. 15, 2013 Hon. Matthew F. Kennelly Zyvox® (linezolid tablets) 5,688,792
AstraZeneca AB v. Watson Labs., Inc.—Florida, 13-1669 (D.N.J.) Mar. 19, 2013 Hon. Joel A. Pisano Nexium® (esomeprazole magnesium delayed-release capsules) 5,714,504; 5,877,192; 6,369,085; 6,875,872; 7,411,070
Pfizer Inc. v. Lupin Ltd., 13-1778 (D.N.J.) Mar. 21, 2013 Hon. Dennis M. Cavanaugh Detrol® LA (tolterodine tartrate extended-release capsules) 6,630,162; 6,770,295
Millenium Pharma., Inc. v. Fresenius KABI USA, LLC, 13-0467 (D. Del.) Mar. 22, 2013 Hon. Gregory M. Sleet Velcade® (bortezomib) 6,713,446; 6,958,319
Takeda Pharma. U.S.A., Inc. v. Amneal Pharma., LLC, 13-0493 (D. Del.) Mar. 28, 2013 Hon. Sue L. Robinson Colcrys® (colchicine) 7,619,004; 7,601,758; 7,820,681; 7,915,269; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,097,655
Mallinckrodt LLC v. Taro Pharma. Indus. Ltd., 13-0494 (D. Del.) Mar. 28, 2013 Hon. Richard G. Andrews Pennsaid® (diclofenac sodium topical solution) 8,217,078
Unimed Pharma., LLC v. Watson Labs., Inc., 13-0496 (D. Del.) Mar. 29, 2013 Hon. Leonard P. Stark AndroGel® (testosterone gel) 6,503,894

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.